Richard S. Levy, EVP, Chief Drug Development Officer at INCYTE CORP (INCY), sold 20,000 shares at $108.13 ($2.2M) on 2015-06-19, disclosed to the SEC on 2015-06-23.
Scheduled sale ($2.2M) by EVP, Chief Drug Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| TARA | BUY | 2025-05-19 | $64K | — | Filing → |
| MDGL | SELL | 2024-11-08 | $1.8M | — | Filing → |
| MDGL | SELL | 2024-11-05 | $2.7M | — | Filing → |